IL147021A0 - Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 - Google Patents

Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1

Info

Publication number
IL147021A0
IL147021A0 IL14702100A IL14702100A IL147021A0 IL 147021 A0 IL147021 A0 IL 147021A0 IL 14702100 A IL14702100 A IL 14702100A IL 14702100 A IL14702100 A IL 14702100A IL 147021 A0 IL147021 A0 IL 147021A0
Authority
IL
Israel
Prior art keywords
compositions
methods
transporter protein
atp binding
binding cassette
Prior art date
Application number
IL14702100A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc, Univ Washington filed Critical Cv Therapeutics Inc
Publication of IL147021A0 publication Critical patent/IL147021A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
IL14702100A 1999-06-18 2000-06-16 Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 IL147021A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14026499P 1999-06-18 1999-06-18
US15387299P 1999-09-14 1999-09-14
US16657399P 1999-11-19 1999-11-19
PCT/US2000/016591 WO2000078971A2 (en) 1999-06-18 2000-06-16 Atp binding cassette transporter protein abc1 popypeptides

Publications (1)

Publication Number Publication Date
IL147021A0 true IL147021A0 (en) 2002-08-14

Family

ID=27385472

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14702200A IL147022A0 (en) 1999-06-18 2000-06-16 Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1
IL14702100A IL147021A0 (en) 1999-06-18 2000-06-16 Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL14702200A IL147022A0 (en) 1999-06-18 2000-06-16 Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1

Country Status (19)

Country Link
EP (2) EP1218515B1 (xx)
JP (4) JP2003508031A (xx)
KR (2) KR20020012612A (xx)
CN (2) CN1379817A (xx)
AR (2) AR024391A1 (xx)
AT (1) ATE422545T1 (xx)
AU (3) AU777461B2 (xx)
BR (2) BR0011753A (xx)
CA (2) CA2375787C (xx)
DE (1) DE60041545D1 (xx)
HK (2) HK1046427A1 (xx)
IL (2) IL147022A0 (xx)
MX (2) MXPA01013174A (xx)
NO (2) NO20016121L (xx)
NZ (3) NZ529785A (xx)
SG (2) SG121853A1 (xx)
TR (2) TR200200440T2 (xx)
TW (2) TWI304737B (xx)
WO (2) WO2000078972A2 (xx)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367955C (en) 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
EP1854880A1 (en) * 1999-03-15 2007-11-14 University of British Columbia Methods and reagents for modulating cholesterol levels
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
WO2001015676A2 (en) * 1999-09-01 2001-03-08 University Of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
US6555323B2 (en) * 2000-02-08 2003-04-29 Pfizer Inc. Assay for ABCA1
EP1280911A2 (en) 2000-05-02 2003-02-05 Aventis Pharma S.A. Regulatory nucleic acid sequences of the ABC1 gene
EP1203588A1 (en) * 2000-11-06 2002-05-08 Bayer Ag Sterol-independent regulation of ABC1 promoter via oncostatinM
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
AU2002317093A1 (en) * 2001-07-03 2003-01-21 University Of British Columbia Screening processes for agents modulating cholesterol levels
JPWO2003033023A1 (ja) * 2001-10-12 2005-02-03 グレラン製薬株式会社 低ｈｄｌ血症改善剤
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003060078A2 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US7265131B2 (en) 2002-12-20 2007-09-04 Exelixis, Inc. Isoquinolinone derivatives and their use as therapeutic agents
BRPI0412262A (pt) 2003-07-23 2006-09-19 X Ceptor Therapeutics Inc derivados de azepina como agentes farmacêuticos
WO2005116057A1 (en) * 2004-05-27 2005-12-08 Baker Medical Research Institute Monoclonal antibody against abca1
DK1888640T3 (da) 2005-05-18 2012-06-18 Ablynx Nv Forbedrede nanobodies mod tumornekrosefaktor-alfa
RU2433139C2 (ru) 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
US8703805B2 (en) 2005-06-27 2014-04-22 Exelixis Patent Company Llc Modulators of LXR
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
EP2070919B1 (en) 2006-11-24 2012-10-10 Hykes Laboratories LLC Spiroquinone compound and pharmaceutical composition
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
WO2008074839A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
KR20100097716A (ko) 2007-11-27 2010-09-03 아블린쓰 엔.브이. 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
WO2009109635A2 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
ES2610622T3 (es) * 2009-03-31 2017-04-28 The General Hospital Corporation Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol
EP2417163B1 (en) 2009-04-10 2019-02-27 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
MX2011012559A (es) 2009-05-28 2012-06-08 Exelixis Patent Co Llc Moduladores de lxr.
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
MX343085B (es) 2010-11-08 2016-10-24 Novartis Ag Polipeptidos que se enlazan a cxcr2.
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
US9101745B2 (en) * 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
WO2014144037A1 (en) 2013-03-15 2014-09-18 Bristol-Myers Squibb Company Lxr modulators
JP6456909B2 (ja) 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
GB201315136D0 (en) * 2013-08-23 2013-10-09 Univ Glasgow Cholesterol modulation
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2017089618A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2018091606A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
TWI826376B (zh) 2017-06-02 2023-12-21 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
TWI802576B (zh) 2017-06-02 2023-05-21 德商馬克專利公司 與ａｄａｍｔｓ結合之免疫球蛋白
EP3630178A1 (en) 2017-06-02 2020-04-08 Merck Patent GmbH Mmp13 binding immunoglobulins
TWI811220B (zh) 2017-06-02 2023-08-11 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
CN115433733A (zh) 2021-06-04 2022-12-06 生物岛实验室 环状RNA Circ-ACE2翻译的多肽及其应用
CN114369162B (zh) 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1280911A2 (en) * 2000-05-02 2003-02-05 Aventis Pharma S.A. Regulatory nucleic acid sequences of the ABC1 gene

Also Published As

Publication number Publication date
JP2003508031A (ja) 2003-03-04
WO2000078972A8 (en) 2001-06-21
AR024391A1 (es) 2002-10-02
EP1218515B1 (en) 2009-02-11
CN1434865A (zh) 2003-08-06
BR0011696A (pt) 2002-04-30
CA2375781A1 (en) 2000-12-28
WO2000078971A2 (en) 2000-12-28
CA2375787C (en) 2007-03-27
CN100513570C (zh) 2009-07-15
NO20016121L (no) 2002-02-12
TWI304737B (en) 2009-01-01
EP1218515A2 (en) 2002-07-03
BR0011753A (pt) 2002-04-30
NO20016114D0 (no) 2001-12-14
KR20020012612A (ko) 2002-02-16
SG121852A1 (en) 2006-05-26
NZ516061A (en) 2004-04-30
NO20016114L (no) 2002-02-12
WO2000078972A2 (en) 2000-12-28
CN1379817A (zh) 2002-11-13
JP2006137750A (ja) 2006-06-01
TR200200441T2 (tr) 2002-11-21
MXPA01013174A (es) 2002-06-04
HK1046427A1 (zh) 2003-01-10
AU5743400A (en) 2001-01-09
KR100476519B1 (ko) 2005-03-17
AR024576A1 (es) 2002-10-16
TWI259205B (en) 2006-08-01
CA2375787A1 (en) 2000-12-28
AU777461B2 (en) 2004-10-14
IL147022A0 (en) 2002-08-14
AU2005200171A1 (en) 2005-02-10
KR20020012281A (ko) 2002-02-15
ATE422545T1 (de) 2009-02-15
NZ531401A (en) 2005-08-26
HK1046708A1 (zh) 2003-01-24
JP4277956B2 (ja) 2009-06-10
WO2000078972A9 (en) 2002-07-18
TR200200440T2 (tr) 2002-09-23
AU5746700A (en) 2001-01-09
SG121853A1 (en) 2006-05-26
TW200626176A (en) 2006-08-01
WO2000078971A3 (en) 2002-01-17
WO2000078972A3 (en) 2002-05-02
JP2003506097A (ja) 2003-02-18
JP2005112859A (ja) 2005-04-28
NO20016121D0 (no) 2001-12-14
EP1190065A2 (en) 2002-03-27
DE60041545D1 (de) 2009-03-26
NZ529785A (en) 2005-09-30
MXPA01013175A (es) 2002-06-04

Similar Documents

Publication Publication Date Title
IL147021A0 (en) Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1
EP1212065A4 (en) COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL
EP1165586A4 (en) TCL-1B GENES AND PROTEINS AND RELATED METHODS AND METHODS
IL212926A0 (en) METHODS FOR ISOLATING AND CHARACTERIZING ENDOGENOUS mRNA-PROTEIN (mRNP) COMPLEXES
AU2002219258A1 (en) Method and system for administering digital collectible cards
IL201751A (en) Compounds that bind il-17-like cytokine and antibodies
AU3808700A (en) Compositions and methods for recombinant adeno-associated virus production
AU5326100A (en) Pharmaceutical compositions and methods for use
AU3864900A (en) Compositions and methods for their preparation from (lepidium)
IL206565A0 (en) An antibody immunospecific for an igs4 polypeptide
AU2977500A (en) Advanced antigen presentation platform
AU2002365111A1 (en) Methods for identifying and using marr family polypeptide binding compounds
EP0987942A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD OF USE
AU6841300A (en) Human antibodies or fragments thereof binding to hla-cw6
AU2002237415A1 (en) Nuclear hormone receptor ligand binding domain
AU8513698A (en) Methods and compositions for designing vaccines
EP1035204A4 (en) STEROID HORMONE BINDING PROTEIN
AU2002316178A1 (en) Compositions and methods for binding agglomeration proteins
NO992217D0 (no) Biopsikassettenhet og fremgangsmÕte for biopsiprepareringer ved bruk av biopsikassettenheten
AU5931600A (en) Lcat recombinant cell line compositions and methods
AU2875600A (en) Methods and compositions for enhancing fibroblast migration
AU5494700A (en) Rna metabolism proteins
AU2002342693A1 (en) Dimeric and multimeric antigen binding structure
GB9929923D0 (en) Antigen preparations
AU4833500A (en) Antibody vaccine for autoimmune diseases